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Abstract 
Background: Helicobacter pylori is a major human pathogenic bacterium in gastric mucosa. Although the association between 
gastric cancer and H. pylori has been well-established, the molecular mechanisms underlying H. pylori-induced carcinogenesis are 
still under investigation. MicroRNAs (miRNAs) are small noncoding RNAs that modulate gene expression at the posttranscrip­
tional level. Recently, studies have revealed that miRNAs are involved in immune response and host cell response to bacteria. Also, 
microRNA-375 (miR-375) is a key regulator of epithelial properties that are necessary for securing epithelium-immune system cross­
talk. It has been recently reported that miR-375 acts as an inhibitor of H. pylori-induced gastric carcinogenesis. There are few reports 
on miRNA-mediated targeting long noncoding RNAs (lncRNAs). 
Objectives: This study aimed to examine the possible eﬀect of miR-375 as an inhibitor of H. pylori-induced carcinogenesis on the 
expression of lncRNA SOX2 overlapping transcript (SOX2OT) and SOX2, a master regulator of pluripotency of cancer stem cells. 
Materials and Methods: In a model cell line, NT-2 was transfected with the constructed expression vector pEGFP-C1 contained miR­
375. The RNA isolations and cDNA synthesis were performed after 48 hours of transformation. Expression of miR-375 and SOX2OT and 
SOX2 were quantiﬁed using real-time polymerase chain reaction and compared with control cells transfected with pEGFP-C1-Mock 
clone. Cell cycle modiﬁcation was also compared after transfections using the ﬂow cytometry analysis. 
Results: Following ectopic expression of miR-375, SOX2OT and SOX2 expression analysis revealed a signiﬁcant decrease in their 
expression level (P < 0.05) in NT-2 cells compared to the control. Cell cycle analysis following ectopic expression of miR-375 in the 
NT-2 cells using propidium iodine staining revealed signiﬁcant extension in sub-G1 cell cycle. 
Conclusions: This is the ﬁrst report to show down-regulation of SOX2OT and SOX2 following induced expression of miR-375. This 
ﬁnding may suggest expression regulation potential between diﬀerent classes of ncRNAs, for example between miR-375 and SOX2OT. 
This data not only extends our understanding of possible ncRNA interactions in cancers but also may open novel investigation lines 
towards elucidation of molecular mechanisms controlling H. pylori inﬂammation and carcinogenesis. 
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1. Background 
Helicobacter pylori is a Gram-negative, microaerophilic, 
spiral-shaped bacterium that colonizes the gastric mucosa. 
Helicobacter pylori infection is the most common bacterial 
infection worldwide and as a major risk factor for gastric 
carcinoma, interferes with cell proliferation and apopto­
sis of the gastric epithelium (1). Helicobacter pylori is a criti­
cal risk factor during the process of gastric carcinogenesis. 
Gastric cancer is one of the most common cancers world­
wide. However, many aspects of molecular mechanism un­
derlying H. pylori-induced gastric carcinogenesis remain to 
be elucidated (2, 3). 
Emerging evidence shows that miRNAs play an impor­
tant role in pathogen-host interactions (4, 5). MicroRNAs 
are a class of small (18 - 22nt) ncRNAs that regulate gene 
expression at the posttranscriptional level. The miRNAs 
make contribution to various cellular processes such as 
cell proliferation, growth, development, cellular stress re­
sponse, and apoptosis. Alterations in the expression of 
miRNAs have been widely reported in numerous diseases 
including almost all types of cancers (6). Act as oncogenes 
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(oncomiRs) or tumor suppressors, miRNAs are playing 
prominent roles in cancer-related processes such as pro­
liferation, apoptosis, metastasis, and angiogenesis. Due to 
their high stability and also their cell- and tissue-speciﬁc 
expression patterns, miRNAs have received tremendous at­
tention as potential diagnostic, prognostic, and therapeu­
tic agents over the past decade (7). 
To date, there are more than 2000 annotated human 
mature miRNAs in the oﬃcial registry (the MicroRNA reg­
istry) (8). Also, miRNAs have been domestrated to mod­
ulate a wide range of biological processes, including cel­
lular development, diﬀerentiation, proliferation, apopto­
sis, metabolism and immune response and microbial in­
fections (9, 10). 
The role of miRNAs in bacterial infections has been ini­
tially demonstrated in plants, in which a miRNA induced 
by Pseudomonas syringae in Arabidopsis thaliana mediates 
the resistance against the bacterium (11). Recent studies 
have characterized deregulation of host miRNAs following 
infection with extracellular (H. pylori) (12), or intracellular 
(Salmonella enterica) (13), Gram-negative bacteria, as well as 
in the response to Gram-positive (Listeria monocytogenes) 
(14) and other pathogenic bacteria (Mycobacterium (15) and 
Francisella species (16)). 
The ﬁrst evidence for the ability of a bacterial pathogen 
to induce changes in the miRNAs of host infected cells was 
obtained from H. pylori. Also, miRNA expression studies in 
response to various bacterial infections have shown com­
mon miRNAs as key regulators in the host innate immune 
response. An increasing number of studies have described 
the occurrence of mysregulation of miRNA expression and 
its involvement in the regulation of gene expression in 
H. pylori-associated gastric cancer. Some miRNAs (let-7b; 
miR-103; miR-370; miR-371-5p; miR-372; miR-373; miR-375; 
miR-449b) are down-regulated, and some miRNAs are up-
regulated (miR-21; miR-25; miR-93; miR-146a; miR-155; miR­
194; 196; miR-200b, 200c; miR-222; miR-223; miR584; miR­
1290) in H. pylori-induced inﬂammation and gastric car­
cinogenesis (17). 
Also, the miR-375 was previously reported to be in­
volved in gastric cancer. Recently, Isomoto et al. found 
that some miRNAs including miR-375 had signiﬁcant cor­
relations with H. pylori-associated gastritis based on endo­
scopic biopsies. Although the complex role of miR-375 in 
diﬀerent cancers has been shown, the role of miR-375 in 
H. pylori-induced gastritis or even gastric carcinogenesis is 
poorly understood (18-20). 
The SRY (sex determining region Y)-box 2 (SOX2) gene 
is a master regulator of pluripotency, lies within an in­
tron region of another gene named as SOX2 overlapping 
transcript (SOX2OT), an lncRNA which is transcribed in the 
same orientation like SOX2. An ncRNA is a functional RNA 
that is not translated into a protein. The genes of ncRNAs 
include highly abundant and functionally important RNAs 
such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), 
as well as RNAs such as snoRNAs, miRNAs, siRNAs, snRNAs, 
piRNAs and the lncRNAs. An increasing number of lncRNAs 
are being identiﬁed, characterized and functionally anno­
tated. lncRNAs are still among the least well-understood of 
RNAs and the underlying mechanisms by which they func­
tion remain largely unexplored. Recent evidences have 
suggested that lncRNAs are biologically functional. Thus, 
lncRNA are receiving attention in molecular medicine (21). 
LncRNAs represent a large fraction of transcriptome 
as a new level of gene expression regulation. lncRNAs are 
found to be involved in epigenetic events, regulation of 
pluripotency and diﬀerentiation processes. Also, lncRNAs 
function as new oncogenes and tumor-suppressor genes. 
Moreover, lncRNAs reveal an enhancer-like function in hu­
man cells. The human genome contains thousands of lncR-
NAs that are expressed at low levels and in a tissue speciﬁc 
manner. LncRNAs are, in general, poorly conserved and 
about one-third of them are primate-speciﬁc (21). 
A few studies describe the interactions between miR-
NAs and lncRNAs. The miRNAs act either as inhibitory de­
coys or as regulatory targets of lncRNA, but such interac­
tions are still poorly explored. While the functions of small 
ncRNAs, such as miRNAs, in the cell have been more un­
derstood, lncRNAs have recently started to emerge as abun­
dant regulators of cell physiology and their functions may 
be diverse (22). Some researchers believe that conserved 
miRNA-lncRNA interactions could not be reliably detected 
with our methodology (23). Here, we focused on the ex­
pression level mainly. 
A recent study revealed miR-375 down-regulation 
in H. pylori inﬂammation and gastric cancerinogenesis. 
The miR-375 has bioinformatically target site on lncRNA 
SOX2OT. In our previous work we revealed SOX2OT upreg­
ulated with master regulators of pluripotency, SOX2 and 
OCT4, in Esophageal Squamous Cell Carcinoma (ESCC). 
The SOX2OT varients diﬀerentially expressed and spliced 
in ESCC. Two novel variants of SOX2OT, SOX2OT-S1 and 
SOX2OT-S2, were up-regulated in ESCC. The novel variants 
of SOX2OT revealed distinct expression patterns and 
down-regulated during the process of neural diﬀerenti­
ation of human embryonic stem cells known as NTERA-2 
or NT-2 cell line (21, 24). There is no report on possible 
miR-375-SOX2OT interaction and the eﬀect of miR-375 on 
SOX2 gene expression so far. 
2. Objectives 
One putative target site has been found on lncRNA 
SOX2OT and SOX2 gene based on sequence homology 
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Figure 1. Conﬁrmation of Insert, miR-375 Precursor, in pEGFP-C1-miR-375 Vector by 
Restriction Digestion and Polymerase Chain Reaction Analysis 
Lane 1 and 2, 334 bp PCR band ampliﬁed by speciﬁc primers for the insert on the bot­
tom; Lanes 3 and 4 are, 100 bp and 1kbp ladders, respectively; Lane 5, single digestion 
of pEGFP-C1-Mock digested with EcoRI produced a 5041 bp-fragment; Lane 6, double-
digest of pEGFP-C1-miR-375 with EcoRI and BamHI produced 334 bp related to miR­
375 precursor insert and 4731 bp vector; Lane 7, single digestion of pEGFP-C1-miR-375 
by EcoRI produced a 5041bp fragment. 
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search for miR-375 sequence using bioinformatics analy­
ses tool miRcode. In this work we aimed to study the pos­
sible eﬀect of miR-375 as an inhibitor of H. pylori-induced 
carcinogenesis on the expression of lncRNA SOX2OT which 
its expression is coregulated with SOX2, a master regulator 
of pluripotency. This study was the ﬁrst step of the pos­
sible miRNA-lncRNA interactions in H. pylori-induced car­
cinogenesis, because there is no report on this possible 
interaction in physiologically or pathologic conditions of 
any cell. 
3. Materials and Methods 
3.1. Finding Putative Target Site for miR-375 on lncRNA SOX2OT 
and SOX2 
Target site for miR-375 has been searched using bioin­
formatic tool named miRcode (www.mircode.org) to ﬁnd 
its complementary seed on SOX2 and SOX2OT transcripts. 
miRcode (designed by institute of biomedicine, univer­
sity of Gothenburg, Sweden) is a comprehensive search 
tool for putative miRNA target sites across the complete 
GENCODE (www.gencodegenes.org) annotated transcrip­
tome, including 10,419 lncRNA genes in the current ver­
sion (miRcode 11, June 2012) The miRcode pipeline is im­
plemented using Matlab, MySQL, Perl, and PHP searches for 
complementary matches to established miRNA seed fami­
lies across GENCODE transcripts (25). 
3.2. Cell Culture 
Human embryonic carcinoma NT-2 stem cells highly 
express SOX2OT and SOX2 genes that is an excellent pro­
totype model of gene expression in pluripotent stem cells 
and diﬀerentiations associated to human embryonic de­
velopment. This cell line was kindly provided by Dr. Pe­
ter Andrews (Sheﬃeld university, UK). Cells were cultured 
in DMEM/F12 medium (invitrogen, carlsbad, CA, USA) sup­
plemented with 10% fetal bovine serum (FBS; invitrogen, 
Carlsbad, CA, USA) and 100 U/mL penicillin/streptomycin 
(Sigma, St Louis, MO, USA) and incubated in a humidiﬁed 
incubator in an atmosphere of 5% CO2 at 37ºC. 
3.3. The miR-375 Expression Plasmid 
The expression plasmid pEGFP-C1 containing miR-375 
and the empty plasmid mock vector were purchased from 
(ParsGenome, Iran). Both plasmids express Neomycin and 
GFP genes to enable selection and detection of transfected 
cells. pEGFP-C1-miR-375 vector contained EcoR1 and BamHI 
sites on their respective 5’ and 3’ ends of miR-375 were 
used to amplify the 334 bp pre-miR-375 sequence by speciﬁc 
primers (Table 1). Restriction enzymes digestions and PCR 
analysis pEGFP-C1-miR-375 vector were performed for con­
ﬁrmation of miR-375 precursor (Table 1 and Figure 1). 















3.4. Ectopic Expression of miR-375 in NT-2 Cells 
The NT-2 cells were seeded at a concentration of 4 × 104 
cells per well in 12-well plates and incubated for 24 hours 
in culture medium. They were transfected with 1.5 µg of 
pEGFP-C1-miR-375 vector in a test culture and 1.5 µg pEGFP-
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C1 mock vectors in a negative control group culture, using 
Lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA) accord­
ing to the manufacturer’s instructions. 
3.5. RNA Extraction 
After 48 hours of transfections, cells were harvested 
and total RNAs were extracted from two test and control 
groups using Trizol reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instruction. The precipi­
tated RNA plate was resuspended in 20 - 30 µL RNase-free 
dH2O and was treated with DNaseI (Sigma, St Louis, MO, 
USA) to remove any DNA contaminations. The quality and 
quantity of total RNA were determined using electrophore­
sis on agarose gel and NanoDrop2000c Spectrophotome­
ter at 260nm (Thermo Fisher ScientiﬁcInc, Wilmington, 
DE, USA) respectively. 
3.6. cDNA Synthesis 
The ﬁrst strand of cDNA for detection of SOX2 and 
SOX2OT expressions was synthesized by Reverse Transcrip­
tase (Takara, Japan), using both oligo dT and random hex­
amer primers (Takara, Japan), according to the manufac­
turer’s instructions. For each sample, a no-reverse tran­
scription (No-RT) control was used in parallel to the DNase­
treated RNA, to detect nonspeciﬁc ampliﬁcation of ge­
nomic DNA. cDNA synthesis for expression analysis of miR­
375 was performed separately by diﬀerent procedure using 
ParsGenome’s miRNA kit (ParsGenome, Iran). 
3.7. Quantitative Real-Time Polymerase Chain Reaction 
Expression of miR-375, SOX2OT and SOX2 were quan­
tiﬁed in transfected NT2 cells with pEGFP-C1-miR-375 and 
pEGFP-C1-Mock vectors 48 hours after transfection. The 
expression level of miR-375 was determined using the 
ParsGenome’s miRNA ampliﬁcation Kit (ParsGenome, 
Iran). 
This was carried out in three main steps including ad­
dition of polyA tail, speciﬁc cDNA synthesis and RT- PCR 
ampliﬁcation, according to the manufacturer’s instruc­
tions. All experiments were performed at least in two du­
plicate using the Bio-Rad thermal cycler (Hercules, Califor­
nia, USA) with the following conditions: 95°C for 10 sec­
onds, 62°C for 10 seconds and 72°C for 30 seconds. Melting 
curve were determined in 60°C to 95°C. U6 was chosen as 
an internal control and PCR eﬃciency for miR-375 and U6 
was measured using standard curves generated by serial 
dilutions of cDNA. 
Speciﬁc RT-PCR primers also were designed for 
SOX2OT and SOX2 and GAPDH using the AlleleID 
6.0 software (Primer BioSoft, Palo Alto, CA, USA; 
www.premierbiosoft.com) and Gene runner software 
(version 3.02; Hastings software Inc.). The sequences of 
forward and reverse primers used for SOX2, SOX2OT and 
GAPDH have been listed in Table 1 (length of products: 162, 
128, 115 bp, respectively) (Table 1 and Figure 2). Takara SYBR 
Premix Ex Taq master mix (2X), supplemented with ROX 
reference Dye II (Takara, Japan), were used for all RT-PCR 
reactions. For compensating variations in the amount 
of input RNA and the eﬃcacy of reverse transcriptase, 
GAPDH mRNA was also quantiﬁed as an internal con­
trol, and related expressions of SOX2 and SOX2OT were 
normalized to its expression value. All RT-PCR reactions 
were carried out by ABI 7500 RT-PCR PCR systems (applied 
biosystems, Foster City, CA) using the following cycling 
conditions: initiation at 94°C for 1 minute, ampliﬁcation 
for 40 cycles with denaturation at 94°C for 10 seconds, 
annealing at 62°C for 10 seconds and extending at 720°C 
for 40 seconds. The expression of a gene was deﬁned based 
on the threshold cycle (Ct), and relative expression levels 
were determined as 2-[Ct of target gene)-(Ct of internal 
control)]. 
Figure 2. Ampliﬁcation of 128 bp Fragment of SOX2OT From cDNA by Designing For­
ward Primer on Exon 1 and Reverse Primer at Junction Between Exon 1 and Exon 2 
3.8. Cell Cycle Analysis by Flow Cytometry 
For cell cycle analysis, cells were collected 48 hours af­
ter transfection with pEGFP-C1-miR-375 or pEGFP-C1-mock 
vectoe as control. The cells were washed in PBS, trypsinized 
with 0.025% trypsin-EDTA to yield single cell suspensions. 
Then, cells ﬁxed in ice-cold 70% ethanol and stained with 
50 µg/mL propidium iodide (PI) solution containing 10 
µg/mL RNaseA (Takara, Japan) and 0.1% Triton X-100. Two 
groups of cells were used for ﬂow cytometric analysis, us­
ing Attune acoustic focusing cytometer (applied biosys­
tems, USA). Experiments were repeated at least twice and 
cell cycle proﬁles were analyzed using ﬂowing software 
version 2.5. 
3.9. Statistical Analysis 
Data are presented as the means ± SD from at least 
three separate experiments. Signiﬁcance was analyzed us­
ing the student’s t-test. The RT-PCR data were adjusted 
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based on the exact PCR eﬃciency. The SPSS software, ver­
sion 17.0 (SPSS, Inc., Chicago, Illinois, USA) was used for per­
forming all the analyses. P < 0.05 were considered as sta­
tistically signiﬁcant diﬀerence. 
4. Results 
4.1. The miR-375 Putative Target Site on lncRNA SOX2OT and 
SOX2 
Bioinformatic and in silico analysis represented a miR­
375 putative target site in the third intron of SOX2OT se­
quence (NR-004053.2) by miRcode, Gene Runner, NCBI 
databases (Figure 3). The SOX2OT gene contains ﬁve exons 
that intron-less gene of SOX2 embedded within the third 
intron of SOX2OT. 
According to our bioinformatic analysis on miR-375 
and SOX2OT transcripts, miR-375 has a putative target site 
on SOX2OT. The SOX2OT gene contains ﬁve exons that 
intron-less gene of SOX2 embedded within the third intron 
of SOX2OT. Seed sequence of mature form of miR-375 has 
been represented in the ﬁrst line. 
4.2. Ectopic Expression of miR-375 in NT2 Cells 
The NT-2 cell line was chosen because of its high 
SOX2OT basal expression and being a model for pluripo­
tent stem cells to study gene expression and diﬀerenti­
ation associated to human embryonic development and 
stem-cell studies. NT-2 cells transfected with pEGFP-C1-miR­
375 (Figure 4A - C) overexpressed miR-375 by about 12-fold 
in comparison to pEGFP-C1-mock transfected cells 48 hours 
after transfection with P < 0.05. 
4.3. Over-Expression of miR-375 Down-Regulates SOX2 and 
SOX2OT 
The expression of SOX2 and SOX2OT was measured us­
ing the RT-PCR. The relative expression of SOX2OT was de­
creased by about 9-fold in pEGFP-C1-miR-375 transfected 
cells in comparison to the pEGFP-C1-mock vector, while 10­
fold down-regulation was observed in SOX2 expression, P < 
0.05 (Figure 4D). 
4.4. Eﬀects of miR-375 Over-Expression on the Cell Cycle Progres­
sion in NT-2 Cells 
The data obtained from ﬂow cytometry cell cycle anal­
ysis following overexpression of miR-375 48 hours after 
transfection in NT-2 cells compared to cells transfected 
with pEGFP-C1-mock as control revealed some eﬀects on 
cell cycle progression. Diﬀerent alterations in the cell cy­
cle were observed in NT-2 cells transfected with pEGFP-C1­
miR-375 compared to control cells. A signiﬁcant decrease 
in the percentage of cells in S phase and G2/M phase was 
observed. Also, a signiﬁcant arrest in sub-G1 and G0/G1 in­
crease was observed in transfected cells with miR-375 (Fig­
ure 4E - G). 
5. Discussion 
In this work, we aimed to study the possible eﬀect of 
miR-375 as an inhibitor of H. pylori-induced carcinogenesis 
on the expression of lncRNA SOX2OT which its expression 
is co-regulates with SOX2, a master regulator of pluripo­
tency. There is no report on possible interaction of miR­
375-SOX2OT in any physiologically or pathologic cells, and 
thus this study maybe the ﬁrst step towards to the pos­
sible miRNA-lncRNA interactions in H. pylori-induced car­
cinogenesis. 
Helicobacter pylori is considered to be a critical risk 
factor of gastric cancer. Related mechanisms by which 
H. pylori could promote cancer are still under investiga­
tion. One proposed mechanism has been called perige­
netic pathway involves enhancement of the transformed 
host cell phenotype by means of alteration in gene expres­
sion without the need for additional mutations in tumor 
suppressor genes (26). The miR-375 is one of the miRNAs 
regulating inﬂammation and carcinogenetic processes in­
duced by H. pylori acts through perigenetic pathway (19, 
27). 
Our ﬁnding from our unbiased bioinformatic analy­
ses showed that SOX2OT has a predicted seed for miR-375. 
MiR-375 has a putative site on SOX2OT intron 3 (AGGGAG) 
and one putative site on SOX2 unique exon sequence. This 
implicated that miR-375 may interact with SOX2OT and 
change its expression level. Two common forward and re­
verse primers were designed on exon 1 and border with 
exon 2 respectively to ampliﬁed 128 bp fragment from all 
common variations of SOX2OT that have been already iden­
tiﬁed consist of SOX2OT, SOX2OT-S1 and SOX2OT-S2. The 
aim of this study was to analyze for the ﬁrst time the ex­
pression regulation of ectopic expression of miR-375 with 
SOX2OT and SOX2 expressions in NT2 cells using RT-PCR. 
Transcription pattern of SOX2OT and SOX2 has been pro­
posed to be regulated in the same manner in pluripotent 
stem cells such as NT2 cells (21). In this study, simulta­
neously decreased expressions of SOX2OT and SOX2 has 
been demonstrated along with miR-375 ectopic expression 
in NT2 cells that is in agreement with the hypothesis pro­
posed by Amaral et al. (24) and Shahryari et al. on the 
possible role of SOX2OT in regulating SOX2 expression. Si­
lencing of SOX2OT by speciﬁc siRNAs in previous study by 
Shahryari et al. (21), found a negative eﬀect on SOX2 expres­
sion as well as a subG1/G1 cell cycle arrest in NT2 cells. 
The observation of SOX2OT down-regulation following 
miR-375 over-expression in this study is in agreement with 
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the cancer stem cell (CSC) theory in gastric carcinogene­
sis (28-30). However, our observation of Asonuma et al. 
(31) about inhibition of SOX2 by H. pylori through IL-4 axis 
and our ﬁnding suggest that more studies are necessary 
for elucidation of the exact mechanism of H. pylori car­
cinogenesis. According to the CSC theory in cancers, stem 
cells are the origin of initiation and development of a can­
cer. In gastric carcinoma, SOX2 is one of the master reg­
ulators of stem-cell pluripotency. Thus, H. pylori may af­
fect the pluripotency of infected cells. The SOX2 gene is 
located in another gene named SOX2OT. We have recently 
demonstrated that SOX2 and SOX2OT are coregulated in 
esophageal squamous cell carcinoma (21). Askarian-Amiri 
et al. (2014) also have recently showed that these two genes 
are co regulated in breast cancer (32). There is no report on 
the relationship between gastric carcinoma and SOX2OT. 
This is the ﬁrst work shows co regulation of SOX2 and 
SOX2OT in a stem cell model. Since SOX2 and SOX2OT bioin­
formatically are targets for miR-375, this ﬁnding maybe of 
importance for the elucidation of H. pylori pathogenesis be­
cause this miRNA is down-regulated in H. pylori infected 
cells and SOX2 is an important regulator of pluripotency. 
Our ﬁnding shows that ectopic miR-375 in NT2 model 
stem cells down-regulates SOX2. The Also, the SOX2 gene 
is a transcription factor critically involved in the pluripo­
tency and stemness of human embryonic stem cells (33). 
SOX2 has recently been identiﬁed as a common target of 
genomic ampliﬁcations and as an oncogene in cancers (34­
36). In addition, SOX2 has been implicated in the function 
of putative cancer stem cells in tumors (37). It has been 
previously reported that immune system has the capac­
ity to target SOX2 (38-40) and several groups have studied 
the presence of humoral responses against SOX2 in can­
cerous cells (40). On the other hand, miR-375 inhibits H. 
pylori-induced inﬂammation and carcinogenesis through 
JAK2/STAT signaling pathway (19). Our ﬁnding implicates 
that previously reported miR-375 down-regulation in H. py­
lori-induced inﬂammation and carcinogenesis (19) may re­
sult in SOX2 up-regulation through which cause H. pylori 
carcinogenesis. Further studies are necessary to establish 
this hypothesis and involved pathways. 
This ﬁnding may broad our knowledge on ncRNAs and 
its possible role in cellular phenomena such as infectious 
diseases. We need further studies to demonstrate that 
whether the eﬀect of miR-375 on SOX2 and SOX2OT can also 
exert by H. pylori infected cells or not. However, this ﬁnd­
ings maybe important to design new strategies for pre­
venting H. pylori-induced-carcinogenesis and are in agree­
ment with the result of Miao et al. (2014) (19). 
In conclusion, our data provides for the ﬁrst time an 
insight into the potential function of the human SOX2OT 
in regulating SOX2 expression and its possible regulation 
by miR-375. It also highlights a co regulation of SOX2OT, 
with key stem cell pluripotency gene, SOX2. Altogether, 
our data has suggested a regulatory mechanism for miR­
375 that may govern the key stem-cell pluripotency gene, 
SOX2, mediated by the lncRNA SOX2OT. 
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A, Phase contrast micrograph X20 and; B, ﬂuorescence micrograph using green ﬁlter show the expression of GFP in transfected NT2 cells 48 hours after transfection with pEGFP­
C1-miR-375. that represent cellular clone expression; C, pEGFP-C1 clone contained precursor of miR-375 insert constructed by ParsGenome Co, Tehran, Iran; D, relative expression 
of SOX2 and SOX2OT in NT-2 cells transfected with pEGFP-C1-miR-375 vector and pEGFP-C1-mock vector as control, Ectopic expression of the miR-375 precursor signiﬁcantly 
reduced the expression of SOX2 and SOX2OT; E and F, alteration in cell cycle distribution following overexpression of miR-375 in NT-2 cells was performed by ﬂow cytometry; 
G, Flow cytometry analysis of NT-2 cells 48 hours after transfection with pEGFP-C1-miR-375 and pEGFP-C1-Mock as control revealed a signiﬁcant increase in sub-G1 and G0/G1 cell 
number and signiﬁcant decrease in S and G2/M cell number after transfection. It suggests sub-G1 extension following ectopic expression of miR-375. 
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Figure 4. NT-2 cell line 
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